Table 4.
Comparison of antimicrobial susceptibilities of MRSA and MSSA.
| Antimicrobial agent | Resistance breakpoint (μg/mL) | MSSA (n = 122) | MRSA (n = 14) | ||||
|---|---|---|---|---|---|---|---|
| Range (μg/mL) | MIC90 (μg/mL) | Resistance (%) | Range (μg/mL) | MIC90 (μg/mL) | Resistance (%) | ||
| MPIPC | 4 | ≦2 | ≦2 | 0 | 4–>8 | >8 | 100 |
| ABPC | 0.5 | ≦0.12 5–>16 | 16 | 71.3 | 4–>16 | >16 | 100 |
| CCL | 16 | 1–16 | 4 | 1.6 | 4–>16 | >16 | 92.9 |
| CDTR | 2* | 0.5 –2 | 1 | 0.8 | 2–>16 | >16 | 100 |
| CAM | 4 | ≦0.125–>16 | >16 | 67.2 | >16 | >16 | 100 |
| CLDM | 1 | ≦0.125–0.25 | 0.25 | 0 | ≦0.125–>16 | >16 | 71.4 |
| FOM | 8** | 0.25–>16 | 16 | 20.5 | 1–>16 | 8 | 14.3 |
| MINO | 8 | ≦0.125–0.25 | ≦0.125 | 0 | ≦0.125–16 | 0.25 | 7.1 |
| GM | 8 | 0.25–>16 | >16 | 54.1 | 1–>16 | >16 | 92.9 |
| VCM | 4 | ≦0.5–1 | 1 | 0 | 1-2 | 1 | 0 |
| NDFX | 4** | ≦0.125–2 | ≦0.125 | 0 | ≦0.125–>16 | ≦0.125 | 7.1 |
| FA | 2** | ≦0.125–>16 | 0.5 | 0.82 | ≦0.125–1 | 0.5 | 0 |
The breakpoints for these antimicrobial agents were determined according to the interpretation criteria of Clinical and Laboratory Standards Institute (CLSI). Susceptibility to antimicrobial drugs for which breakpoints are not determined by CLSI was according to the interpretation criteria of the Japan Society for Chemotherapy (*) or defined in this study (**).